← Hims Hers Health overview

Hims Hers Health vs Alignment Healthcare LLC: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Hims Hers Health Inc (HIMS)

Q3 2026
▲2▼2

Hims & Hers grew fast but faced FTC suit and cash burn

  • Strong revenue and subscriber growth Revenue jumped 38% to $753.2M and subscribers rose 18.5% to about 2.9 million, prompting management to raise full-year guidance to $3.1–3.3 billion. This shows the core business is still expanding quickly.

    It explains the main positive force behind the quarter's results.

  • GLP-1 momentum and international expansion Barclays raised its price target to $39, citing momentum in weight-loss drugs (GLP-1s), helped by the Novo Nordisk partnership and the Eucalyptus acquisition that expands into the UK, Australia, and Canada.

    It highlights a key growth driver and analyst optimism that supported the stock.

  • FTC lawsuit and legal probes An FTC lawsuit over health-data sharing and deceptive billing sank the stock 14.7% and triggered multiple law-firm investigations. This regulatory risk weighed heavily on investor sentiment.

    It was the biggest negative event that hurt the stock during the quarter.

  • Financial deterioration and operational issues Q2 swung to a $0.37 loss, gross margin fell to about 64%, free cash flow turned negative $68M, and Visa placed HIMS in a chargeback-monitoring program. Leadership departures and a 51% yearly stock drop fueled takeover talk.

    It shows the financial and operational setbacks that pressured the stock.

August 2026
▼2▲1

Hims & Hers: strong sales but losses, legal and payment risks hit stock

  • Revenue and subscriber growth beat expectations Revenue rose 38% to $753.2M, beating estimates, and full-year guidance was raised to $3.1–$3.3B. Subscribers grew 18.5% to about 2.9 million, showing demand for its health and weight-loss services remains strong.

    This is the main positive force behind the stock, showing the business is still growing quickly.

  • Profit turned to loss as costs and margins worsened Q2 swung to a $0.37 loss from a $0.17 profit, gross margin fell to about 64% from 76%, free cash flow turned negative $68M, and operating expenses jumped 48.4%. This shows growth is coming at a high cost.

    This explains why the stock fell despite strong revenue, as profitability and cash flow deteriorated.

  • Visa dispute program and lawsuits raise risk Visa placed HIMS in a dispute-monitoring program over weight-loss subscription chargebacks, while FTC, state, and class-action lawsuits over billing and privacy raise costs and reputational risk. These issues threaten its payment processing and trust with customers.

    This is a new negative development that adds to legal and operational uncertainty, weighing on the stock.

  • Leadership change and takeover talk amid weak stock The chief accounting officer is departing, and the stock fell 51% in a year, prompting takeover speculation despite CEO voting control and about $1B convertible debt. JPMorgan initiated at Neutral with a $32 target, citing execution risk in branded GLP-1s.

    This captures the mixed sentiment: management turnover and a weak stock invite takeover talk, but analysts see execution risk.

Latest
▼2

HIMS: legal risk, leadership exit, and a 51% slump reshape the story

  • Privacy investigations and class action raise legal risk Law firms are investigating and suing Hims & Hers over claims it shared users' private health data and mishandled billing. Legal fights like this can bring fines, payouts, and bad publicity, which weighs on the stock because investors worry about cost and reputation.

    New legal and regulatory threats are a fresh, material drag on HIMS.

  • Chief accounting officer to leave in October Hims & Hers said its chief accounting officer, Irene Becklund, will depart on October 9, 2026, after seven years. The CFO will cover the role while a replacement is found. A key finance leader leaving adds uncertainty, which can pressure the stock.

    A senior finance departure is a new event that creates uncertainty for investors.

  • Stock down 51% makes HIMS a takeover candidate After a 51% one-year drop, Hims & Hers is being talked about as a possible acquisition target for Amazon, UnitedHealth, CVS, or Pfizer, though its CEO controls voting shares and about $1 billion in convertible debt complicates any deal. Takeover talk can support the stock, but the weak price and debt are negatives.

    The steep decline and buyout speculation are new and directly shape how investors value HIMS.

  • JPMorgan starts coverage at Neutral with $32 target JPMorgan began covering Hims & Hers with a Neutral rating and a $32 price target, saying growth is strong but the shift to branded weight-loss drugs like Wegovy carries execution risk. A neutral start with a target near the current price gives little fresh upside push.

    A major bank's first rating is a new signal that frames the bull and bear case.

▼3▲1

Visa billing crackdown and FTC lawsuit hit HIMS; growth stays strong

  • Visa puts HIMS in dispute-monitoring program Visa placed Hims & Hers in its Acquirer Monitoring Program after a surge in credit-card disputes tied to weight-loss subscriptions, with a possible $75,000 penalty and a requirement to keep disputes below 1.5% for three months. This threatens billing reliability and could slow subscriber growth, pushing the stock down.

    This is the main new negative event this period and directly pressures HIMS's price.

  • FTC and state regulators escalate legal action The FTC and state regulators filed a civil enforcement action, and a consumer class action targets privacy and subscription practices. The CEO says the FTC misunderstands the company, but the legal fight adds costs and reputational risk that weigh on the stock.

    This is a new escalation of the legal pressure that is a core driver of HIMS's risk profile.

  • Q2 revenue jumps 38% and outlook raised Hims & Hers raised its 2026 revenue outlook to $3.1–$3.3 billion after Q2 sales rose 38.2% to $753.2 million, beating estimates. Subscribers grew 18.5% to about 2.9 million, showing demand is still strong and supporting the stock.

    This is the main new positive fundamental update this period and shows the growth story remains intact.

  • Margins shrink and cash burn deepens Gross margin fell to 63.8% from 76%, operating expenses rose 48.4%, and free cash flow was negative $68 million with an $86.3 million net loss. The company is spending heavily to grow, which pressures profits and keeps the stock volatile.

    This is the key counterweight to the revenue beat and explains why the stock still faces pressure.

▼2

HIMS Q2 loss and margin hit overshadow revenue beat

  • Q2 loss and margin collapse Hims & Hers reported a second-quarter loss of $0.37 per share, swinging from a $0.17 profit a year earlier. Gross margin fell to 64% from 76%, hit by an $81 million one-time cost tied to the Eucalyptus acquisition, a weight-loss strategy shift, and FTC legal reserves. This profit miss is what pushed the stock down.

    The earnings miss and margin drop are the main new financial event driving the stock lower this period.

  • Revenue beat and raised guidance Revenue rose 38% to $753.2 million, beating the roughly $699 million analysts expected, and the company raised its full-year revenue outlook to $3.1 billion to $3.3 billion. This shows demand is still strong, but investors focused on the loss and costs, so the stock still fell.

    It is the positive counterweight in the same earnings report and explains why the selloff was not larger.

  • CEO defends FTC lawsuit, touts cheaper GLP-1s CEO Andrew Dudum said the FTC lawsuit is more about publicity than a real resolution, and he expects cash-paying patients to eventually pay $40 to $50 a month for branded weight-loss drugs, down from $150 to $200. Cheaper pricing could boost demand, but the lawsuit still threatens fines and trust.

    It updates the biggest legal overhang and gives a concrete path to lower prices that could help future demand.

  • Weight-loss pill market cost pressure Hims & Hers and Novo Nordisk both fell even after strong growth, as investors worried about rising costs in the weight-loss pill market. Novo Nordisk's Wegovy pill sales missed expectations, adding to concerns that the branded GLP-1 push may be less profitable than hoped.

    It shows the cost and competition pressure in the core weight-loss business that is weighing on HIMS shares.

July 2026
▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

▲2▼2

HIMS: FTC privacy lawsuit and law firm probes hit growth story

  • GLP-1 inflection and FDA peptide decision Barclays raised its price target to $39, citing a clear pickup in Hims & Hers' GLP-1 weight-loss business after the Novo Nordisk partnership, with website traffic up 35% and app users up 21%. A July FDA committee decision on peptides could open another growth avenue.

    This is the main positive force behind the stock and explains why it had been rising before the FTC news.

  • Novo Nordisk deal and Eucalyptus acquisition expand reach Hims & Hers is deepening its move into prescription weight management by offering Novo Nordisk's Wegovy and Ozempic, and its Eucalyptus acquisition adds scale in the UK, Australia, and Canada. This broadens revenue sources but raises questions about margins and regulatory exposure.

    It shows the concrete business expansion driving the growth narrative, a key reason investors were optimistic.

  • FTC lawsuit over data sharing and billing The FTC sued Hims & Hers, alleging it shared users' health data with advertisers like Meta and Snap and used deceptive billing and cancellation practices. The stock fell about 14.7% on the news, as the lawsuit threatens fines, reputational damage, and its core trust-based business model.

    This is the biggest new negative event and the main reason the stock dropped sharply this period.

  • Multiple law firm investigations into securities law violations Several law firms, including Holzer & Holzer, Frank R. Cruz, Kessler Topaz, and Lowey Dannenberg, are investigating whether Hims & Hers misled investors about the FTC allegations. These probes can lead to class-action lawsuits, adding legal costs and uncertainty that weigh on the stock.

    It shows the FTC issue is escalating into potential investor lawsuits, a fresh negative overhang.

Alignment Healthcare LLC (ALHC)

Q3 2026
▼3▲1

ALHC: Strong H1 Growth Undone by Legal, Regulatory, and Ratings Setbacks

  • Strong H1 2026 Results and Raised Guidance Alignment Healthcare reported robust first-half 2026 results, with Q1 revenue up 33.3% to $1.24B and Q2 up 31.6% to $1.34B, beating estimates. Membership grew ~31.5% and adjusted EBITDA rose 60%, prompting raised full-year guidance.

    This positive operational performance was a key driver of investor sentiment during the period.

  • Whistleblower Lawsuit and Accounting Concerns A former executive's whistleblower lawsuit alleges misclassified expenses and accounting irregularities, triggering securities investigations and a 16.7% stock drop. Potential restatements could erode trust and lead to further volatility.

    This legal and accounting issue directly caused a sharp stock decline and raised serious governance concerns.

  • Medicare Advantage Prior-Authorization Bill Threat A bipartisan Medicare Advantage prior-authorization bill threatens higher medical loss ratios and compliance costs, causing shares to fall 12.6%. If passed, it could pressure margins and require operational changes.

    This regulatory risk weighed on the stock and could impact future profitability.

  • CMS Star Rating Downgrade for Largest Contract CMS downgraded Alignment's largest California contract to 3.5 stars, covering ~81% of members, cutting bonus payments from 2028 and sending shares down over 20%. This also means Q3 EBITDA will dip to $20–30M due to heavy H2 spending.

    The rating downgrade directly reduces future revenue and triggered a major stock sell-off.

September 2026
▼3▲1

ALHC hit by whistleblower probe, star downgrade; guidance raised

  • Whistleblower accounting probe A former executive's whistleblower complaint alleges accounting irregularities and misclassified expenses, prompting a securities law investigation. The stock fell 16.7% on the news. If true, it could force financial restatements and erode investor trust, weighing on the shares.

    This is a new, serious regulatory and credibility risk that directly pressures ALHC's stock.

  • Raised 2026 outlook on strong first half Alignment raised full-year 2026 guidance after membership jumped 31.5% and first-half adjusted EBITDA rose 60%. But management plans heavy second-half spending, so third-quarter EBITDA is projected at just $20–30 million versus $68.1 million in Q2. The growth is real but near-term profit will dip.

    It shows the underlying business is growing and management is confident, a positive counterweight to the bad news.

  • Medicare Advantage prior authorization bill A bipartisan bill would force MA plans to honor prior authorizations and ban retroactive payment clawbacks. If passed, it would raise medical loss ratios and compliance costs for insurers like Alignment. The stock fell 12.6% on the news.

    This is a new regulatory threat that could squeeze ALHC's margins and profitability.

  • Medicare star rating downgrade CMS downgraded Alignment's largest California contract to 3.5 stars from 4, covering about 81% of its members. That cuts quality bonus payments starting in 2028, hitting future revenue. The stock fell over 20% on the day, a major blow to earnings outlook.

    This is the most severe new negative event, directly reducing future federal funding and investor confidence.

Latest
▼3▲1

ALHC hit by whistleblower probe, star downgrade; guidance raised

  • Whistleblower accounting probe A former executive's whistleblower complaint alleges accounting irregularities and misclassified expenses, prompting a securities law investigation. The stock fell 16.7% on the news. If true, it could force financial restatements and erode investor trust, weighing on the shares.

    This is a new, serious regulatory and credibility risk that directly pressures ALHC's stock.

  • Raised 2026 outlook on strong first half Alignment raised full-year 2026 guidance after membership jumped 31.5% and first-half adjusted EBITDA rose 60%. But management plans heavy second-half spending, so third-quarter EBITDA is projected at just $20–30 million versus $68.1 million in Q2. The growth is real but near-term profit will dip.

    It shows the underlying business is growing and management is confident, a positive counterweight to the bad news.

  • Medicare Advantage prior authorization bill A bipartisan bill would force MA plans to honor prior authorizations and ban retroactive payment clawbacks. If passed, it would raise medical loss ratios and compliance costs for insurers like Alignment. The stock fell 12.6% on the news.

    This is a new regulatory threat that could squeeze ALHC's margins and profitability.

  • Medicare star rating downgrade CMS downgraded Alignment's largest California contract to 3.5 stars from 4, covering about 81% of its members. That cuts quality bonus payments starting in 2028, hitting future revenue. The stock fell over 20% on the day, a major blow to earnings outlook.

    This is the most severe new negative event, directly reducing future federal funding and investor confidence.

July 2026
▲2▼1

Whistleblower Lawsuit and Investigations Hit ALHC Despite Strong Results

  • Whistleblower lawsuit and securities investigations A former executive sued on July 8, claiming Alignment misclassified expenses to inflate profits and pay. The stock fell 16.7%, and multiple law firms launched investigations, raising legal costs and uncertainty.

    This is the main new negative event that drove the stock down in July.

  • Strong Q1 and Q2 revenue growth Alignment reported Q1 revenue up 33.3% to $1.24 billion and Q2 revenue up 31.6% to $1.34 billion, both beating estimates. Membership grew to 294,100, and the medical benefits ratio improved.

    These results show underlying business strength that supports the stock despite legal issues.

  • Higher 2026 Star Ratings Improved Star Ratings for 2026 could lead to higher future reimbursement from Medicare, boosting revenue and profitability. This is a positive fundamental development for the company.

    Star Ratings are a key driver of future Medicare payments and thus a positive catalyst.

▲1▼1

Legal Cloud Grows as Strong Q2 Earnings Beat Estimates

  • More law firms join accounting investigation Kaplan Fox, Holzer & Holzer, Hagens Berman, Lowey Dannenberg, and Frank R. Cruz all launched or continued investigations into Alignment's accounting. This keeps the whistleblower scandal alive, raising legal costs and uncertainty that weigh on the stock.

    This is the main new negative force this period, extending the legal overhang from earlier reports.

  • Q2 revenue and profit beat expectations Alignment reported Q2 revenue of $1.34 billion, up 31.6%, and earnings per share of $0.17, both above analyst estimates. Membership grew to 294,100, and the medical benefits ratio improved, showing the core business is strong.

    This is the only new positive fundamental news this period, providing a counterweight to the legal issues.

▼2▲1

Whistleblower Accounting Claims Trigger Investigations, Stock Plunge

  • Strong Q1 Earnings and Membership Growth Alignment Healthcare reported Q1 revenue of $1.24 billion, up 33.3% year-over-year, with earnings per share beating expectations. Membership grew by 48,500 to 284,800, and analysts raised full-year earnings estimates. Higher Star Ratings across all plans for 2026 could boost future reimbursement. This positive news initially pushed the stock up 10.7%.

    This is a key positive driver that contrasts with the negative news later in the period, providing a balanced view.

  • Whistleblower Lawsuit Alleges Financial Manipulation On July 8, a former executive filed a whistleblower lawsuit alleging Alignment misclassified operating expenses as capital expenditures to inflate adjusted EBITDA and boost stock price and executive pay. The company denies the claims and vows to defend itself. The stock fell 16.7% on the news, its worst drop since February 2024.

    This is the primary negative event that caused a sharp stock decline and triggered multiple investigations.

  • Multiple Law Firms Launch Investigations Following the whistleblower lawsuit, law firms Block & Leviton, Hagens Berman, Kaplan Fox, and Bragar Eagel & Squire announced investigations into Alignment for potential securities law violations. These investigations could lead to lawsuits and further pressure the stock as legal costs and uncertainty rise.

    These investigations amplify the negative impact and keep the issue in the spotlight, affecting investor sentiment.